ZYCUBO® (copper histidinate), First FDA-Approved Treatment for Patients with Menkes Disease, Exclusively Available at Biologics by McKesson in the United States
Biologics by McKesson became the exclusive specialty pharmacy provider for ZYCUBO, the first FDA-approved treatment for pediatric patients with Menkes disease.
OJEMDA (tovorafenib), FDA Approved for Pediatric Low-Grade Glioma, Available at Biologics by McKesson
Biologics by McKesson joined a limited network as a specialty pharmacy provider for OJEMDA, an oral RAF inhibitor for pediatric low-grade glioma.